Lonza Group (FRA:LO3A) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LO3A Lonza Group Ltd FRA:LO3A
85 GF Score
Price €57.50
GF Value €60.68
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Lonza Group Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:LO3A
85GF Score
Lonza Group Ltd FRA:LO3A
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lonza Group (FRA:LO3A) Overvalued in 2026?

Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued. The current stock price of €57.50 is trading 5.2% below its estimated GF Value™ of €60.68. GuruFocus considers Lonza Group to be Fairly Valued.

Key valuation signals for FRA:LO3A:

  • Dividends Received:
  • GF Value™: €60.68 vs. price of €57.50 (5.2% below fair value)
  • GF Score™: 85/100 with 4 warning signs

No single metric tells the full story. See the FRA:LO3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lonza Group Business Description

Address Muenchensteinerstrasse 38, Basel, CHE, 4002
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
85GF Score

Get the complete analysis for FRA:LO3A

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€57.50
Price
€60.68
GF Value